Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Early rheumatoid arthritis].

F Atzeni1, P Sarzi-Puttini

  • 1Unità di Reumatologia, Azienda Ospedaliera Polo Universitario L. Sacco, Milano, Italia. atzenifabiola@hotmail.com

Reumatismo
|July 3, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Sex and gender differences in comorbidities in spondyloarthritis: a focus on psoriatic arthritis.

Reumatismo·2024
Same author

The Italian Society for Rheumatology clinical practice guidelines for the diagnosis and management of fibromyalgia Best practices based on current scientific evidence.

Reumatismo·2021
Same author

Serum klotho concentrations inversely correlate with the severity of nailfold capillaroscopic patterns in patients with systemic sclerosis.

Reumatismo·2019
Same author

The role of klotho in systemic sclerosis.

Reumatismo·2018
Same author

Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics' register GISEA.

Clinical rheumatology·2017
Same author

EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update.

Annals of the rheumatic diseases·2016
Same journal

Delayed referral, socioeconomic status, and disease characteristics as factors associated with disabilities in rheumatoid arthritis patients: a multicenter observational study.

Reumatismo·2026
Same journal

Telerheumatology to improve first access outcomes in outpatients: a prospective monocentric pilot study.

Reumatismo·2026
Same journal

Hypocomplementemic urticarial vasculitis: a rare presentation revealing systemic lupus erythematosus and Sjögren's disease.

Reumatismo·2026
Same journal

Is there still someone laughing at Christopher Columbus?

Reumatismo·2026
Same journal

Concurrent herpetic hypertensive anterior uveitis and cytomegalovirus retinitis in a non-HIV patient with melanoma differentiation-associated gene-5 dermatomyositis: intravenous immunoglobulin comes to the rescue.

Reumatismo·2026
Same journal

Myasthenic syndrome in systemic lupus erythematosus successfully treated with plasma exchange: through one of the unexplored faces of neuropsychiatric involvement.

Reumatismo·2026
See all related articles

Early rheumatoid arthritis (RA) treatment is crucial to prevent irreversible joint damage. Aggressive therapies, including disease-modifying anti-rheumatic drugs (DMARDs) and TNF-alpha inhibitors, show promise in early RA management.

Area of Science:

  • Rheumatology
  • Immunology
  • Pharmacology

Context:

  • Rheumatoid arthritis (RA) is a systemic autoimmune disease causing chronic joint inflammation and damage.
  • Early diagnosis and intervention are critical due to rapid, irreversible joint damage within the first two years of onset.
  • Current predictive markers and imaging techniques have limitations in distinguishing early RA from non-RA conditions.

Purpose:

  • To review the importance of early intervention in RA management.
  • To discuss the "window of opportunity" hypothesis for therapeutic intervention in early RA.
  • To explore the current evidence and interest in early treatment strategies, including DMARDs and TNF-alpha inhibitors.

Summary:

  • Early treatment of RA is vital to prevent joint damage and preserve function.

Related Experiment Videos

  • The "window of opportunity" suggests a critical period for enhanced therapeutic response in early RA.
  • Evidence supports early DMARDs therapy, with aggressive approaches and TNF-alpha inhibitors showing significant interest for early RA management.

    • Impact:

    • Highlights the need for timely diagnosis and aggressive treatment strategies in early RA.
    • Emphasizes the potential for sustained benefits or even cure with effective early intervention.
    • Informs clinical practice regarding the growing interest in advanced therapies like TNF-alpha inhibitors for early RA.